AIMS: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND RESULTS: A post-hoc analysis was performed of the ASCEND-HF trial. The EuroQOL five dimensions questionnaire (EQ-5D) was administered to study participants at baseline, 24 h, discharge/day 10, and day 30. EQ-5D includes functional dimensions mapped to corresponding utility scores (i.e. 0 = death and 1 = perfect health), and a visual analogue scale (VAS) ranging from 0 (i.e. 'worst imaginable health state') to 100 (i.e. 'best imaginable health state'). The association between baseline and discharge EQ-5D measurements and subsequent clinical outcomes including death and rehospitalization were assessed using multivariable logistic regression and Cox proportional hazards regression. A total of 6943 patients (97%) had complete EQ-5D data at baseline. Mapped utility and VAS scores (mean ± SD) increased over time, respectively, from 0.56 ± 0.23 and 45 ± 22 at baseline to 0.67 ± 0.26 and 58 ± 22 at 24 h and to 0.79 ± 0.20 and 68 ± 22 at discharge, and remained stable at day 30. Lower mapped utility scores at baseline [odds ratio (OR) per 0.1 decrease in utility score 1.03, 95% confidence interval (CI) 1.00-1.06] and discharge (OR 1.10, 95% CI 1.05-1.15) and VAS scores at baseline (OR per 10 point decrease 1.05, 95% CI 1.01-1.09) were significantly associated with increased risk of 30-day all-cause death or HF rehospitalization. CONCLUSIONS: Patients hospitalized for HF had severely impaired health status at baseline and, although this improved substantially during admission, health status remained abnormal at discharge.
AIMS: A longitudinal and comprehensive analysis of health-related quality of life (HRQOL) was performed during hospitalization for heart failure (HF) or soon after discharge. METHODS AND RESULTS: A post-hoc analysis was performed of the ASCEND-HF trial. The EuroQOL five dimensions questionnaire (EQ-5D) was administered to study participants at baseline, 24 h, discharge/day 10, and day 30. EQ-5D includes functional dimensions mapped to corresponding utility scores (i.e. 0 = death and 1 = perfect health), and a visual analogue scale (VAS) ranging from 0 (i.e. 'worst imaginable health state') to 100 (i.e. 'best imaginable health state'). The association between baseline and discharge EQ-5D measurements and subsequent clinical outcomes including death and rehospitalization were assessed using multivariable logistic regression and Cox proportional hazards regression. A total of 6943 patients (97%) had complete EQ-5D data at baseline. Mapped utility and VAS scores (mean ± SD) increased over time, respectively, from 0.56 ± 0.23 and 45 ± 22 at baseline to 0.67 ± 0.26 and 58 ± 22 at 24 h and to 0.79 ± 0.20 and 68 ± 22 at discharge, and remained stable at day 30. Lower mapped utility scores at baseline [odds ratio (OR) per 0.1 decrease in utility score 1.03, 95% confidence interval (CI) 1.00-1.06] and discharge (OR 1.10, 95% CI 1.05-1.15) and VAS scores at baseline (OR per 10 point decrease 1.05, 95% CI 1.01-1.09) were significantly associated with increased risk of 30-day all-cause death or HF rehospitalization. CONCLUSIONS:Patients hospitalized for HF had severely impaired health status at baseline and, although this improved substantially during admission, health status remained abnormal at discharge.
Authors: C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Andrew P Ambrosy; Peter S Pang; Sadiya Khan; Marvin A Konstam; Gregg C Fonarow; Brian Traver; Aldo P Maggioni; Thomas Cook; Karl Swedberg; John C Burnett; Liliana Grinfeld; James E Udelson; Faiez Zannad; Mihai Gheorghiade Journal: Eur Heart J Date: 2013-01-04 Impact factor: 29.983
Authors: Marco Metra; John G Cleland; Beth Davison Weatherley; Howard C Dittrich; Michael M Givertz; Barry M Massie; Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Gad Cotter Journal: Eur J Heart Fail Date: 2010-03-12 Impact factor: 15.534
Authors: Eldrin F Lewis; Marc A Pfeffer; Amy Feng; Hajime Uno; John J V McMurray; Robert Toto; Shravanthi R Gandra; Scott D Solomon; Moustafa Moustafa; Iain C Macdougall; Francesco Locatelli; Patrick S Parfrey Journal: Clin J Am Soc Nephrol Date: 2011-01-06 Impact factor: 8.237
Authors: Marco Metra; Christopher M O'Connor; Beth A Davison; John G F Cleland; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Michael M Givertz; George A Mansoor; Daniel M Bloomfield; Gang Jia; Paul DeLucca; Barry Massie; Howard Dittrich; Gad Cotter Journal: Eur Heart J Date: 2011-03-08 Impact factor: 29.983
Authors: Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf Journal: Am Heart J Date: 2008-12-19 Impact factor: 4.749
Authors: Robert J Mentz; Adrian F Hernandez; Amanda Stebbins; Justin A Ezekowitz; G Michael Felker; Gretchen M Heizer; Dan Atar; John R Teerlink; Robert M Califf; Barry M Massie; Vic Hasselblad; Randall C Starling; Christopher M O'Connor; Piotr Ponikowski Journal: Eur J Heart Fail Date: 2012-11-15 Impact factor: 15.534
Authors: Yanhong Li; Matthew P Neilson; David J Whellan; Kevin A Schulman; Wayne C Levy; Shelby D Reed Journal: J Card Fail Date: 2013-05 Impact factor: 5.712
Authors: Marat Fudim; Kishan S Parikh; Allison Dunning; Adam D DeVore; Robert J Mentz; Phillip J Schulte; Paul W Armstrong; Justin A Ezekowitz; W H Wilson Tang; John J V McMurray; Adriaan A Voors; Mark H Drazner; Christopher M O'Connor; Adrian F Hernandez; Chetan B Patel Journal: Am J Cardiol Date: 2018-08-03 Impact factor: 2.778
Authors: Gian Luca Di Tanna; Blake Angell; Michael Urbich; Peter Lindgren; Thomas A Gaziano; Gary Globe; Björn Stollenwerk Journal: Pharmacoeconomics Date: 2022-08-12 Impact factor: 4.558
Authors: Johan S Bundgaard; Kasper Iversen; Mia Pries-Heje; Nikolaj Ihlemann; Sabine U Gill; Trine Madsen; Hanne Elming; Jonas A Povlsen; Niels E Bruun; Dan E Høfsten; Kurt Fuursted; Jens J Christensen; Martin Schultz; Flemming Rosenvinge; Jannik Helweg-Larsen; Lars Køber; Christian Torp-Pedersen; Emil L Fosbøl; Niels Tønder; Claus Moser; Henning Bundgaard; Ulrik M Mogensen Journal: Qual Life Res Date: 2022-03-29 Impact factor: 3.440
Authors: Justin T Parizo; Jeremy D Goldhaber-Fiebert; Joshua A Salomon; Kiran K Khush; John A Spertus; Paul A Heidenreich; Alexander T Sandhu Journal: JAMA Cardiol Date: 2021-08-01 Impact factor: 30.154
Authors: John K Peel; Rafael Neves Miranda; David Naimark; Graham Woodward; Mamas A Mamas; Mina Madan; Harindra C Wijeysundera Journal: J Am Heart Assoc Date: 2022-04-12 Impact factor: 6.106
Authors: Mohammad A Alnajashi; Mohammed A Almasoud; Sami A Aldaham; Juan Manuel Acuña; Juan C Zevallos Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889
Authors: Kelsey M Flint; John A Spertus; Fengming Tang; Philip Jones; Timothy J Fendler; Larry A Allen Journal: BMC Cardiovasc Disord Date: 2017-03-14 Impact factor: 2.298